Consun Pharmaceutical Group Limited (FRA:C1P)

Market Cap	1.47B +1.7%
Revenue (ttm)	468.20M +11.2%
Net Income	151.42M +16.5%
EPS	0.18 +17.2%
Shares Out	n/a
PE Ratio	9.28
Forward PE	8.88
Dividend	0.09 (5.11%)
Ex-Dividend Date	Sep 8, 2026

Volume	404
Open	1.680
Previous Close	1.660
Day's Range	1.680 - 1.680
52-Week Range	1.340 - 2.180
Beta	n/a
Analysts	n/a
Price Target	n/a
Est. Earnings	Nov 26, 2026

About FRA:C1P

Consun Pharmaceutical Group Limited, together with its subsidiaries, produces and sells pharmaceutical products in Mainland China. It operates through two segments, Consun Pharmaceutical and Yulin Pharmaceutical. The company offers uremic clearance granules for chronic renal failure; Yishen Huashi particles for proteinuria; TCM to treat diabetic kidney disease; Gadopentetate Dimeglumine injections for nervous centralis, stomach, chest, pelvic cavity, and extremities, as well as for renal function assessment; Iopamidol injections for neuroradiol...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1997
• Employees: 2,847
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: C1P

Financial Performance

In 2025, FRA:C1P's revenue was 3.42 billion, an increase of 15.17% compared to the previous year's 2.97 billion. Earnings were 1.08 billion, an increase of 18.41%.

Financial numbers in CNY

Data Sources: S&P Global Market Intelligence and Twelve Data

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Twelve Data.

Last checked:

Oct 26, 2026

Data Sources Report a data error